Clinical trials: Chronic Obstructive Pulmonary Diseases
Chronic Obstructive Pulmonary Disease
NVA237 Versus Placebo 12-week Efficacy Study
The study serves to determine whether the treatment of patients with stable, symptomatic Chronic Obstructive Pulmonary Disease (COPD) with the investigational drug NVA237 is efficient and safe.
- Trial name
- NCT01709864
- Testing
- NVA237
- Where
- 54 sites in United States
- Volunteers
- 440 people
- Sponsor
- Novartis Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Comparison of Safety and Efficacy of the Combination Product QVA149A Against the Concurrent Administration of the Individual Components, QAB149 and NVA237, in Patients With Chronic Obstructive Pulmonary Disease (COPD)
The study assessed the safety and efficacy of the fixed combination product QVA149 versus the component products QAB149 and NVA237, administered concurrently, in patients that have moderate to severe chronic obstructive pulmonary…
- Trial name
- BEACON (NCT01529632)
- Testing
- QVA149, NVA237, QAB149
- Where
- 26 sites in Austria, Denmark and 3 more
- Volunteers
- 193 people
- Sponsor
- Novartis Pharmaceuticals
Pulmonary Disease, Chronic Obstructive
Effect of Spiriva® on Health-related Quality of Life in Chronic Obstructive Pulmonary Disease (COPD) Patients Who Stopped Smoking During Treatment.
Post marketing Surveillance to gain insights into the effects of therapy with Spiriva® (tiotropium bromide) on health-related quality of life in COPD patients who stopped smoking during treatment and to obtain safety data…
- Trial name
- NCT02172547
- Testing
- Spiriva
- Volunteers
- 10,821 people
- Sponsor
- Boehringer Ingelheim
Asthma
WEUKBRE5554: IMI PROTECT(Work Package 2): Beta2 Agonists and Acute Myocardial Infarction
The studies described in this protocol are all performed within the framework of PROTECT (Pharmacoepidemiological Research on Outcomes of Therapeutics by a European ConsorTium) Work Package 2 and Workgroup 1.
- Trial name
- NCT01636726
- Testing
- Inhaled LABA use
- Volunteers
- 1 people
- Sponsor
- GlaxoSmithKline
COPD
A Study of RPL554 Drug Administered by Metered Dose Inhaler to Treat Chronic Obstructive Pulmonary Disease
The purpose of this study is to investigate 5 doses of RPL554 and placebo, administered by pressurized metered dose inhaler (pMDI), in patients with moderate to severe chronic obstructive pulmonary disease (COPD).
- Trial name
- NCT04091360
- Testing
- Part A: RPL554, Part B: RPL554
- Where
- 2 sites in United Kingdom
- Volunteers
- 40 people
- Sponsor
- Verona Pharma, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA
Pulmonary Disease, Chronic Obstructive
Efficacy and Safety of the Addition of Fluticasone Propionate/Salmeterol (250/50mcg) Twice-daily to 2 Doses of Umeclidinium Bromide Inhalation Powder (62.5 or 125mcg) Once-daily Over 12 Weeks.
The purpose of this 12 week study is to evaluate the effects of the addition of umeclidinium bromide (62.5mcg) once-daily to fluticasone propionate (250/50mcg) twice-daily and umeclidinium bromide (125mcg) once-daily to…
- Trial name
- NCT01772147
- Testing
- Umeclidinium bromide 62.5mcg, Umeclidinium bromide 125mcg, Fluticasone propionate 250mcg/Salmeterol 50mcg
- Where
- 55 sites in United States, Chile and 3 more
- Volunteers
- 608 people
- Sponsor
- GlaxoSmithKline
Non-cystic Fibrosis Bronchiectasis、Chronic Sinusitis Without Nasal Polyps、Chronic Obstructive Pulmonary Disease
Study on Drug Interactions Affecting the Pharmacokinetics of RSS0343 Tablet
This study is a single-center, single-sequence, self-controlled, open design, aiming to investigate the effects of rifampicin and clarithromycin on the pharmacokinetics of RSS0343 in humans.
- Trial name
- NCT07696091
- Testing
- RSS0343 Tablet; Rifampicin Capsules, RSS0343 Tablet; Clarithromycin Tablets
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Reistone Biopharma Company Limited
Pulmonary Disease, Chronic Obstructive
INTREPID: Investigation of TRELEGY Effectiveness: Usual Practice Design
The primary purpose of this study is to assess the effectiveness of TRELEGY ELLIPTA relative to non-ELLIPTA Multiple Inhaler Triple Therapies (MITT) for Chronic Obstructive Pulmonary Disease (COPD) control within the usual…
- Trial name
- NCT03467425
- Testing
- FF/UMEC/VI, Inhaled Corticosteroid, LAMA
- Where
- 143 sites in Germany, Netherlands and 3 more
- Volunteers
- 3,109 people
- Sponsor
- GlaxoSmithKline
Asthma
Albuterol HFA MDI in Pediatric Participants With Asthma
The primary objective of this study is to evaluate the chronic-dose and efficacy of Albuterol-HFA-MDI relative to placebo in pediatric asthmatics.
- Trial name
- NCT00577655
- Testing
- Albuterol, Proventil® HFA
- Where
- 13 sites in United States
- Volunteers
- 103 people
- Sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Safety and Pharmacokinetics of Inhaled Doses of GSK233705 and GW642444 in Healthy Subjects.
GW642444 and GSK233705 are in development for treatment of Chronic Obstructive Pulmonary Disease. Development of these two inhaled drugs as a combination therapy would have potential for improved patient benefit as they both work…
- Trial name
- NCT00671216
- Testing
- GSK233705, GW642444, GSK233705 and GW642444
- Where
- United Kingdom
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
COPD
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease
Study to Assess the Safety and Tolerability of PT010, PT009 and PT003 in Subjects with Moderate to Very Severe Chronic Obstructive Pulmonary Disease
- Trial name
- NCT02536508
- Testing
- BGF MDI 320/14.4/9.6 μg, GFF MDI 14.4/9.6 μg, BFF MDI 320/9.6 μg
- Where
- 64 sites in United States
- Volunteers
- 627 people
- Sponsor
- Pearl Therapeutics, Inc.
Migraine
Treatment for Migraines With an Implantable Device
The purpose of this study is to evaluate the safety and effectiveness of an implantable device for difficult to treat migraine. There are a significant number of patients who have drug refractory migraine and alternative…
- Trial name
- NCT00286078
- Testing
- Precision
- Where
- 15 sites in United States
- Volunteers
- 179 people
- Sponsor
- Boston Scientific Corporation
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Clinical Outcome of Corticosteroids in the Treatment of COPD Exacerbations in China
This is a Post-hoc analysis based on the database of "A non-interventional, retrospective study on AECOPD treatment status in China".
- Trial name
- CONTAIN (NCT03633838)
- Where
- China
- Volunteers
- 5,067 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease
Safety, Preliminary Pharmacokinetics and Bronchodilator Properties of V0162
Pulmonary administered anticholinergic agents have shown their importance in the chronic obstructive pulmonary disease (COPD) management to reduce morbidity, disability and mortality.
- Trial name
- NCT01348555
- Testing
- Bronchodilatator
- Where
- 2 sites in Belgium, France
- Volunteers
- 108 people, healthy volunteers welcome
- Sponsor
- Pierre Fabre Medicament
Pulmonary Disease, Chronic Obstructive
Pharmacokinetic Study in Elderly Patients With Chronic Obstructive Bronchitis (COPD)
Study to evaluate the pharmacokinetics of tiotropium following 14 days of administration (18µg once per day) in elderly COPD patients.
- Trial name
- NCT02172326
- Testing
- Tiotropium inhalation capsules for oral inhalation
- Volunteers
- 29 people
- Sponsor
- Boehringer Ingelheim
Chronic Obstructive Pulmonary Disease
14729-D9831C00002- 1 Month Biopsy Study
The purpose of this study is to study histological changes, cellularity, clinical efficacy and safety of AZD1981 in patients with Chronic Obstructive Pulmonary Disease
- Trial name
- Biopsy (NCT00766415)
- Testing
- AZD1981
- Where
- 8 sites in Germany, Netherlands and 1 more
- Volunteers
- 52 people
- Sponsor
- AstraZeneca
COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbation
A Repeat Ascending Dosing Study of the Safety and Clinical Activity of R-3750 in Patients With Mild to Moderate COPD
The goal of this study is to determine the safety and tolerability of orally taken probiotic (R-3750) in patients with mild to moderate chronic obstructive pulmonary disease (COPD)
- Conditions
- COPD (Chronic Obstructive Pulmonary Disease), COPD Exacerbation, COPD Exacerbation Acute
- Trial name
- R-3750-01-LU (NCT07076290)
- Testing
- R-3750
- Volunteers
- 27 people
- Sponsor
- Rise Therapeutics LLC
Bronchitis, Chronic
Telithromycin: in the Treatment of Acute Exacerbation of Chronic Bronchitis in Adult Outpatients With COPD
Non-inferiority efficacy of telithromycin versus azithromycin
- Trial name
- NCT00538148
- Testing
- Telithromycin
- Volunteers
- 668 people
- Sponsor
- Sanofi
Chronic Obstructive Pulmonary Disease (COPD)
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week…
- Trial name
- OPTIMIZE (NCT02165826)
- Testing
- Roflumilast, Standard of Care COPD Treatment
- Where
- 2 sites in Slovakia
- Volunteers
- 1,323 people
- Sponsor
- AstraZeneca
Pulmonary Disease, Chronic Obstructive
GSK573719 IV Enabling Study
A single-centre, open-label, sequential, cross-over study to examine the safety, tolerability and pharmacokinetics of 3 ascending single intravenous doses, a single 1000μg oral dose and a single 1000μg inhaled dose of GSK573719…
- Trial name
- NCT01110018
- Testing
- GSK573719 (SOLUTION), GSK573719 (INHALATION POWDER)
- Where
- United Kingdom
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.